What is CAI's 12-month price target and RQD AI Jury consensus?

CAI's 12-month base price target is $34.27 (range $26.32 to $40.44), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / CAI

HSIC (58) OSCR (53) MOH (57) GRAL (54) ⌘ Pro Terminal →

Caris Life Sciences Inc. (CAI) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell CAI stock right now?

Caris Life Sciences Inc. (CAI) currently earns a Roarable Rating of B (Buy — BUY) with 73/100 RQD Confidence. High-quality cash engine (steady margins, 4% return on capital) with steady institutional support.

$32.10 -6.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $31.80

Caris Life Sciences Inc. (CAI) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (steady margins, 4% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $9.70B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CAI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Caris Life Sciences Inc. (NASDAQ: CAI) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $32.10 (-6.50% 1D, market cap $9.70B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, CAI ranks #47 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CAI compare to HSIC and OSCR in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), CAI carries a Roarable B (73/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 4.4%. By comparison, HSIC (Henry Schein Inc.) holds a D+ grade (58/100 RQD, P/E 23.0x, ROIC 11.2%, cap $9.46B) and OSCR (Oscar Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.37B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CAI?

▼

Per CAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002019410), Caris Life Sciences Inc. generated $812.0M in revenue (+97.0% YoY), -$68.1M in net income, and $66.9M in free cash flow against $1.13B in total assets and $378.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $31.80 (-0.93%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 8.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAI)Realized 20D OHLCV Swing Band: ±12.4%

Deterministic 5-Pillar Attribution (73/100 Composite)

🔍 WHY CAI SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.4% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 9.79 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Disciplined Float (-0.04% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$30.25+6.9% Next Q

Q2 (-2Q)

Grade B-$32.35+9.6% Next Q

Q3 (-1Q)

Grade B$35.45-9.4% Next Q

Current

Grade B$32.10+7.1% Hist 90D α

Trajectory: C+ (65) → B (73)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CAI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, CAI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.69) or 200D SMA ($21.71) invalidates the momentum regime and cuts Target Base ($34.27) toward Bear Floor ($26.32).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CAI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 73%NO 27%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

58.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

9.79>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE80% OF RANGE

L: $14$32.10H: $37

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on CAI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (70)

4.4% ROIC with 42.0% gross margin and 0.65% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 9.79 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (72)

30/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like CAI

✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CAI Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CAI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +71.75%▲ ASCENDING CHANNEL

2026-11-03O $36.14H $36.14L $32.10C $32.10VOL 3.67M

RES: $37.19SUP: $16.51SMA50: $29.69SMA200: $21.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CAI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CAI Butterfly Map → + Track CAI →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

14.6%/yr Implied 5Y Growth

vs. +97.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CAI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CAI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CAI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAI)

Health Care Rank #47 of 1015 ⚔️ HSIC vs CAI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CAI vs. HSIC, OSCR, MOH, GRAL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Caris Life Sciences Inc. (CAI) ranks #47 by composite RQD confidence (73/100, grade B) and #114 by equity capitalization ($9.70B). Within this direct 5-issuer industry benchmark cohort, MOH leads on earnings valuation at 22.0x trailing P/E, while MOH leads on capital efficiency and profitability with 17.2% ROIC and 13.1% gross margin. CAI currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CAI ACTIVE Caris Life Sciences Inc.	B	73/100	—	—	4.4%	-6.50%	$9.70B	Benchmark Subject
HSIC Henry Schein Inc.	D+	58/100	23.0x	31.1%	11.2%	+2.05%	$9.46B	/hsic-vs-cai →
OSCR Oscar Health Inc.	D+	53/100	—	—	-35.0%	+2.07%	$9.37B	/oscr-vs-cai →
MOH Molina Healthcare Inc	D+	57/100	22.0x	13.1%	17.2%	+1.79%	$10.69B	/moh-vs-cai →
GRAL GRAIL Inc.	D+	54/100	—	—	-18.0%	-6.74%	$6.41B	/gral-vs-cai →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002019410 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Caris Life Sciences Inc. (CAI) reported GAAP revenue of $812.0M (+97.0% vs. FY2024 revenue of $412.3M , and +165.3% cumulative change since FY2023) , GAAP net income of -$68.1M, operating cash flow of $83.2M, and free cash flow of $66.9M (+126.4% YoY). On the balance sheet, CAI closed FY2025 with $1.13B in total assets against $378.8M in total debt (Altman Z-Score: 9.79, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$812.0M	-$68.1M	$83.2M	$66.9M	$1.13B	$378.8M
FY2024 (FY)	2024-12-31	$412.3M	-$281.9M	-$245.2M	-$253.6M	$343.7M	$319.4M
FY2023 (FY)	2023-12-31	$306.1M	-$341.4M	-$276.1M	-$289.9M	$5.62B	$1.31B

3. CAI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CAI compare to HSIC and OSCR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CAI?

Where is CAI trading relative to its 50-day, 200-day, and 52-week technical levels?

CAI last traded at $32.10 (-6.50% on volume of 3,257,733 shares), positioning the stock +8.12% above its 50-day simple moving average ($29.69) and +47.86% above its 200-day simple moving average ($21.71). Across its 52-week range of $14.19 to $36.50, CAI sits at the 80.3% percentile with a 14-day RSI of 58.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.4% ($28.12 to $36.08).

Direct Sub-Reports: CAI RQD Cockpit CAI 12M Forecast CAI Earnings & Move CAI Dividends & DRIP CAI Insiders & 13F CAI Whale Options CAI Profit Sankey CAI News & Why

ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ SEC XBRL & RQD VERIFIED

CAI — Caris Life Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Caris Life Sciences Inc. (CAI) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $32.10 (-6.50% 1D, market capitalization $9.70B).

Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 4.4%, gross margin of —, operating margin of 5.6%, and free cash flow yield of 0.65%.
Whale 13F & Options Flow (18/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (13/20) + Forensic Balance Sheet (16/20): Incorporates a 0.91x equity beta, Altman Z-Score of 9.79, Piotroski F-Score of 8/9, and Debt/Equity of 0.66x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Caris Life Sciences Inc. Is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry. The profile identifies the company's market capitalization as $10.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Caris Life Sciences Inc. (CAI) reported $812.0M in annual revenue (up from $412.3M in FY2024, +97.0% YoY) and -$68.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($306.1M revenue, -$341.4M net income) through FY2025, CAI scaled operating cash flow to $83.2M and free cash flow to $66.9M, backed by $1.13B in total assets against $378.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 73/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $14.19 – $36.50 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 95.0x EV/EBITDA against 5.6% operating margins and a 0.91x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), CAI carries a macro regime beta of 0.91 and gross margin of —.

Key Question #1: Can CAI sustain or expand its 5.6% operating margin and 4.4% ROIC against Medical Specialities peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $812.0M and free cash flow of $66.9M, how will capital allocation balance growth reinvestment against $378.8M in total debt?
Key Question #3: How sensitive is CAI's 21.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.91x)?

CAI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Caris Life Sciences Inc. (CAI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CAI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 22h ago

Caris Life Sciences, Inc. (CAI) stock price, news, quote and history

Yahoo Finance UK report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Caris Life Sciences (NasdaqGS:CAI) Stock Forecast & Analyst Predictions

Simply Wall St report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Caris Life Sciences, Inc. Stock 12‑Month Price Target Raised to $30.23, Implies 10% Upside

TradingView report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Caris Life Sciences (NASDAQ:CAI) Shares Up 7.6% - Still a Buy?

MarketBeat report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Caris Life Sciences (CAI) Stock Price, News & Analysis

Stock Titan report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Caris Life Sciences (NASDAQ:CAI) Stock Price Target Raised at JPMorgan Chase & Co.

MarketBeat report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for

Yahoo Finance report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Jordan Spieth stars in a campaign for an AI-powered blood test to help detect cancer early

Stock Titan report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CAI Bull vs. Bear Conversation Board — What's Your Call at $32.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CAI 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $39.48 (+15.0%)

📌 Pinned Debate

Per the Roarable RQD rating, institutional accumulation (18/20) and a strong balance sheet (Altman Z 9.79, Piotroski F 8/9) support the

Per the Roarable RQD rating, institutional accumulation (18/20) and a strong balance sheet (Altman Z 9.79, Piotroski F 8/9) support the stock's B grade.. When you look under the hood at CAI, Fundamental Cash Engine is 14/20 with 0.0% gross margins and 4.4% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (18/20) has been quietly accumulating below $36.50. My 12M target is $39.48.

RetailWhale_TX 🐂 BULL

@BearTrap_Alert Shorting a 18/20 institutional whale-flow stock at $34.33 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $28.49 (-17.0%)

Spot @ $34.33

Per the market data, EV/EBITDA of 95 and FCF yield of 0.65% leave valuation stretched against thin cash returns and negative trailing E

Per the market data, EV/EBITDA of 95 and FCF yield of 0.65% leave valuation stretched against thin cash returns and negative trailing EPS of -0.24.. Look at the math on CAI: paying 21.0x forward P/E for 4.4% ROIC and 5.6% operating margins leaves zero margin of safety if Medical Specialities demand softens. I'd wait for a retest of $30.21 before getting long.